22
Participants
Start Date
February 13, 2020
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
Cipaglucosidase Alfa
Enzyme Replacement Therapy via intravenous infusion
Miglustat
Participants received Cipaglucosidase Alfa (ATB200) co-administered with Miglustat(AT2221)
WITHDRAWN
National Taiwan University Hospital, Taipei
RECRUITING
Women's and Children's Hospital, North Adelaide
RECRUITING
UPMC Children's Hospital of Pittsburgh, Pittsburgh
RECRUITING
San Gerardo Hospital, Monza
RECRUITING
Lysosomal and Rare Disorders Research and Treatment Center, Inc., Fairfax
RECRUITING
Duke University Medical Center, Durham
NOT_YET_RECRUITING
Woodruff Memorial Research Building, Atlanta
RECRUITING
Wolfson Children's Hospital, Jacksonville
RECRUITING
University of Florida Clinical Research Center, Gainesville
RECRUITING
Cincinnati Children's Hospital Medical Center, Cincinnati
WITHDRAWN
Infusion Associates, Grand Rapids
WITHDRAWN
Mayo Clinic, Rochester
RECRUITING
St. Louis Children's Hospital, St Louis
RECRUITING
SphinCS GmbH Clinical Science for LSD, Hochheim am Main
WITHDRAWN
Arkansas Children's Hospital, Little Rock
RECRUITING
University of Utah, Clinical and Translational Sciences Institute, Salt Lake City
WITHDRAWN
Neuromuscular Research Center, Phoenix
WITHDRAWN
UCSF Benioff Children's Hospital, Oakland
COMPLETED
University of Calgary, Calgary
RECRUITING
Izumi City General Hospital, Osaka
RECRUITING
Gunma University Hospital, Gunma
RECRUITING
Tohoku University Hospital, Miyagi
RECRUITING
Tokyo Women's Medical University, Tokyo
Lead Sponsor
Amicus Therapeutics
INDUSTRY